MSH2 and prostate cancer: In four of seven hypermutated cases MMR mutations were complex structural rearrangements in MSH2 and MSH6. We conclude that somatic rearrangements in MSH2 and MSH6 are an important mechanism leading to hypermutation and MSI in advanced prostate cancer.